ES2422429T3 - Diagnóstico del cáncer de próstata - Google Patents

Diagnóstico del cáncer de próstata

Info

Publication number
ES2422429T3
ES2422429T3 ES06708357T ES06708357T ES2422429T3 ES 2422429 T3 ES2422429 T3 ES 2422429T3 ES 06708357 T ES06708357 T ES 06708357T ES 06708357 T ES06708357 T ES 06708357T ES 2422429 T3 ES2422429 T3 ES 2422429T3
Authority
ES
Spain
Prior art keywords
prostate cancer
cancer diagnosis
diagnosis
vivo use
antibody labeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06708357T
Other languages
English (en)
Inventor
David Ulmert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diaprost AB
Original Assignee
Diaprost AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diaprost AB filed Critical Diaprost AB
Application granted granted Critical
Publication of ES2422429T3 publication Critical patent/ES2422429T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Abstract

Un anticuerpo marcado con un trazador específico para hK2 para su uso in vivo en el diagnóstico del cáncer depróstata.
ES06708357T 2005-02-17 2006-02-17 Diagnóstico del cáncer de próstata Active ES2422429T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/059,944 US8663600B2 (en) 2005-02-17 2005-02-17 Diagnosis of prostate cancer
PCT/EP2006/060067 WO2006087374A1 (en) 2005-02-17 2006-02-17 Diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
ES2422429T3 true ES2422429T3 (es) 2013-09-11

Family

ID=36200197

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06708357T Active ES2422429T3 (es) 2005-02-17 2006-02-17 Diagnóstico del cáncer de próstata

Country Status (13)

Country Link
US (2) US8663600B2 (es)
EP (1) EP1858929B1 (es)
JP (1) JP5602989B2 (es)
CN (1) CN101137672A (es)
AU (1) AU2006215586B2 (es)
CA (1) CA2597687C (es)
CY (1) CY1114386T1 (es)
DK (1) DK1858929T3 (es)
ES (1) ES2422429T3 (es)
PL (1) PL1858929T3 (es)
PT (1) PT1858929E (es)
SI (1) SI1858929T1 (es)
WO (1) WO2006087374A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2785848A1 (en) * 2009-12-01 2011-06-09 The University Of Tokushima Radiation intensity measuring apparatus for encapsulated sealed radioactive source for brachytherapy
US20140308204A1 (en) * 2011-10-25 2014-10-16 Memorial Sloan Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
BR112014010739A2 (pt) * 2011-10-28 2017-04-25 Fredax Ab agentes terapêuticos e uso dos mesmos
BR112014021776B1 (pt) * 2012-03-05 2022-08-09 Opko Diagnostics, Llc Sistema de ensaio e método para a determinação de uma probabilidade de um evento associado com o câncer da próstata
CN102866153B (zh) * 2012-09-29 2014-08-13 郑州安图生物工程股份有限公司 前列腺炎联合检测试剂盒
JP6381033B2 (ja) * 2012-10-12 2018-08-29 国立大学法人弘前大学 前立腺癌と前立腺肥大を識別するための方法およびキット
EP3553088A1 (en) 2013-11-19 2019-10-16 Fredax AB Humanised anti kallikrein-2 antibody
MX2016012667A (es) 2014-03-28 2017-01-09 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
CN107406510B (zh) 2015-03-27 2022-02-18 欧普科诊断有限责任公司 前列腺抗原标准品及其用途
JP6916797B2 (ja) 2015-10-05 2021-08-11 フレダックス・アクチエボラーグ 抗体ポリペプチド及びそれらの使用
CN105243283B (zh) * 2015-11-06 2019-04-19 吴志宏 前列腺癌诊疗信息采集系统
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
EP0974057B1 (en) * 1996-07-15 2005-09-21 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
AU737659B2 (en) 1996-11-14 2001-08-23 Hybritech Incorporated Method for detection of metastatic prostate cancer
FI980488A (fi) * 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US7250291B1 (en) * 1998-08-07 2007-07-31 Dana-Farber Cancer Institute Tumor antigens and uses thereof
FI990382A0 (fi) * 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US7053042B1 (en) * 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
CA2448355A1 (en) * 2001-05-25 2002-12-05 Mount Sinai Hospital Method of detecting and monitoring prostate and ovarian cancers

Also Published As

Publication number Publication date
US8663600B2 (en) 2014-03-04
CY1114386T1 (el) 2016-08-31
EP1858929A1 (en) 2007-11-28
US20060182682A1 (en) 2006-08-17
AU2006215586B2 (en) 2012-08-30
EP1858929B1 (en) 2013-04-24
DK1858929T3 (da) 2013-07-01
CN101137672A (zh) 2008-03-05
CA2597687C (en) 2015-12-01
WO2006087374A1 (en) 2006-08-24
SI1858929T1 (sl) 2013-11-29
PT1858929E (pt) 2013-07-26
JP2008530183A (ja) 2008-08-07
US20110097276A1 (en) 2011-04-28
PL1858929T3 (pl) 2013-09-30
AU2006215586A1 (en) 2006-08-24
CA2597687A1 (en) 2006-08-24
JP5602989B2 (ja) 2014-10-08

Similar Documents

Publication Publication Date Title
ES2422429T3 (es) Diagnóstico del cáncer de próstata
ES2507520T3 (es) Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático
CR11274A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
CR20110553A (es) Terapia complementaria contra el cáncer
ECSP109940A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y métodos de uso
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
CR10325A (es) Diagnosticos y tratamientos para tumores
CL2011001186A1 (es) Uso de un anticuerpo anti-vegf para tratar cancer de mama localmente recurrente o metastasico en un sujeto en asociacion con un agente quimioterapeutico y kit.
ECSP10010438A (es) ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS Y METODOS DE USO
AR050264A1 (es) Uso de tinturas de cianina para el diagnostico de enfermedades asociadas con angiogenesis
BRPI0510674A (pt) variantes fc otimizadas
SV2007002227A (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
CR20110559A (es) Anticuerpos específicos para cadherina-17
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
AR060440A1 (es) Agonistas receptores de eritropoietina
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
BRPI0809079A2 (pt) tratamento de câncer com um combinado de il-18 humana e anticorpo anti-cd20
MX350807B (es) Composiciones y metodos para el analisis de cancer de prostata.
ES2572368T3 (es) Tratamiento de la artrosis
EA201100882A1 (ru) Профилактическое/терапевтическое средство против рака
CL2012000387A1 (es) Método para tratar a un paciente diagnosticado con cáncer de mama previamente tratado metastásico que comprende la combinación de una quimioterapia con la administración de un anticuerpo anti-vegf; y kit utilizado.